Cambridge, MA, July 13, 2017 —The Universitätsklinikum Erlangen (UK Erlangen) has joined the TriNetX health research network, becoming the first healthcare organization in Germany to join TriNetX. The UK Erlangen dataset covers more than one million patient lives and makes demographic, diagnoses, medications, and lab data available for query on the TriNetX network.
TriNetX is a network comprised of healthcare organizations representing over 84 million patients globally, biopharmaceutical companies, and contract research organizations (CROs). UK Erlangen joins other network members who are working together to improve protocol design, site selection, patient recruitment, and collaborative research across a range of therapeutic areas and development stages.
“We have been looking to establish a comprehensive infrastructure to support translational research for the hospital and our faculty for many years,” said Hans-Ulrich Prokosch, Chief Information Officer at UK Erlangen. “We have been evaluating platforms to support local feasibility studies and to connect us with a network of biopharmaceutical companies. We felt TriNetX provided the best solution.”
Founded in 1815, UK Erlangen is located in Bavaria in southern Germany and serves the Erlangen/Nuremberg metropolitan area. UK Erlangen, the University of Erlangen-Nuremberg, and the city of Erlangen are collaborating with scientific, commercial, and political partners to gain an international leadership position in the field of optimal healthcare and best medical engineering. UK Erlangen is also the coordinating site for the MIRACUM consortium in Germany and was a founding member of the Electronic Health Records for Clinical Research (EHR4CR) project.
“We selected TriNetX because of their ability to easily load data from our i2b2 data warehouse which minimized the ETL process from our side,” said Prokosch. “We were also impressed with their data security and governance concepts as well as their user-friendly interface for identifying and exploring patient cohorts.”
“Sponsors conduct most trials on a global scale so adding prestigious international healthcare organizations like UK Erlangen to the network is critical,” said Gadi Lachman, CEO of TriNetX. “Like their U. S. peers, international clinical research sites want to connect with biopharma and get more trials, have a need to perform research on their own data, and love to collaborate with other global sites. With the right data governance and regulatory framework, they are very comfortable achieving these goals through TriNetX.”
Network members utilize TriNetX’s cloud-based, health research platform to analyze patient populations with search criteria across multiple longitudinal data points. TriNetX’s advanced analytics modules provide intelligence on the most impactful criteria as well as identifying the rate at which new patients present. Each de-identified data point in the TriNetX network can be traced to healthcare organizations who then are able to identify individual patients, allowing clinical researchers to develop virtual patient cohorts that can be found in real-world clinical trial settings. Researchers can discover patients for industry-sponsored and investigator-initiated studies, as well as for collaboration with peer research institutions.
“We now hope that the TriNetX platform will be actively used by our medical researchers at Erlangen University to identify feasible cohorts based on routinely documented EHR data for future research projects,” said Prokosch. “We are looking forward to successful connections with biopharmaceutical companies which might enable further clinical trials with UK Erlangen as a participating partner.”
####
About Universitätsklinikum Erlangen
Located in Bavaria in the south of Germany, the Universitätsklinikum Erlangen generates first class medical achievements for patients recovering from physical, mental, and social illnesses. They promote the advancement in research, teaching, and medical care through knowledge exchange with external resources. They serve 64,000 inpatients and conduct 520,000 outpatient visits annually in the Erlangen/Nuremberg metropolitan area. For more information, visit: The Universitätsklinikum Erlangen, www.uk-erlangen.de/en
About TriNetX
TriNetX is the global health research network enabling healthcare organizations, biopharma and contract research organizations (CROs) to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. Each member of our community shares in the consolidated value of our global, federated health research network that connects clinical researchers in real-time to the patient populations which they are attempting to study. For more information, visit https://trinetx.com/.
Media Contacts:
Jennifer Haas
TriNetX
P: (978) 697-3921
E: jennifer.haas@trinetx.com
Barbara Mestel
Universitätsklinikum Erlangen
P: (0049)9131 85 46678
E: presse@uk-erlangen.de
